B BIOXCEL THERAPEUTICS INC
| Market Cap | $31.95M |
| P/E Ratio | — |
| Forward P/E | -0.72 |
| Dividend Yield | — |
| Beta | 0.30 |
| 52W Range | $1.18 - $6.80 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Howard Marks Oaktree Capital Management | 0.01% | $385.00K | 241,188 | — |
Frequently Asked Questions
What is BTAI stock price today?
BIOXCEL THERAPEUTICS INC (BTAI) is currently trading at $1.18. The stock has a 52-week range of $1.18 to $6.80 and a market capitalization of $31.95M.
Is BTAI a good stock to buy in 2026?
BIOXCEL THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of -35.2%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling BTAI stock?
There have been 0 insider transactions for BTAI in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has BTAI stock performed over the past year?
BIOXCEL THERAPEUTICS INC (BTAI) has returned -35.2% over the past 12 months. The stock traded between $1.18 and $6.80 during this period, and is currently at $1.18.
Which hedge funds own BTAI (BIOXCEL THERAPEUTICS INC)?
1 tracked hedge funds currently hold BTAI in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is BTAI's market cap and valuation?
BIOXCEL THERAPEUTICS INC (BTAI) has a market capitalization of $31.95M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is BTAI's revenue and profitability?
BIOXCEL THERAPEUTICS INC reported revenue of $642.00K with net income of N/A and a profit margin of N/A. The stock has a beta of 0.30.
What sector is BTAI in and who are its biggest institutional holders?
BIOXCEL THERAPEUTICS INC (BTAI) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.